Revvity’s EUROIMMUN launches solution for specific typing of Alzheimer’s disease associated APOE gene

Revvity, Inc., announced today the launch of the in-vitro diagnostic EURORealTime™ APOE assay in European countries that accept the CE mark, which will enable accurate genotyping of the APOE gene. APOE genotyping is valuable to assess a patient’s risk for side effects prior to the start of an anti-amyloid (beta) therapy for Alzheimer’s disease.

Introducing Meteor™ chips on the IsoSpark™ platform: Advancing handsfree quantitative proteomics

We are pleased to introduce Meteor™ chips on the IsoSpark™ platform.

September 18, 2023

Numinus Announces Partnership with MAPS to Support Therapist Psychedelic Experiential Training | Psychedelic Invest

Numinus Wellness Inc., (TSX: NUMI / OTCQX: NUMIF), a mental health care company advancing innovative treatments and evidence-based investigational psychedelic-assisted therapies, announced a partnership with the

June 16, 2023

IQVIA and Propel abandon merger after FTC probe and injunction

IQVIA is calling off its acquisition of Propel Media and health tech marketer DeepIntent. The companies agreed to abandon the deal after an FTC probe

January 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.